30,000 COPD Patients in England to Get New Lung Treatment

Breathing easier just became possible for thousands of people across England and Wales. The National Institute for Health and Care Excellence has approved dupilumab, a self-administered injection that could transform life for adults battling uncontrolled chronic obstructive pulmonary disease.

The treatment targets patients who still struggle despite using standard inhaler therapies. To qualify, patients must have experienced at least one severe flare-up or two moderate episodes in the past year, plus show elevated levels of a specific blood cell called an eosinophil.

Dupilumab works differently than traditional COPD medications. Patients inject themselves every two weeks using a pre-filled pen, and the drug tackles inflammation at its source by blocking specific immune system signals. Clinical trials showed impressive results: patients using dupilumab averaged less than one major flare-up per year, compared to more than one flare-up for those on placebo.

This approval breaks a long drought in COPD innovation. No new biologic treatments have reached NHS patients for this specific lung condition until now, leaving many people cycling through the same limited options. The drug already proved its worth treating severe asthma since 2021.

Sarah Sleet from Asthma + Lung UK called the decision "a major milestone for COPD treatment." She pointed out that fewer than one in 10 COPD patients currently receive the basic care they need to stay healthy, highlighting how much room exists for improvement beyond new medications.

The approval carries extra significance because COPD hits hardest in communities that need support most. Men over 40 and people from lower-income backgrounds face higher rates of the disease. NICE's committee specifically noted that more people from disadvantaged areas would benefit from this treatment, potentially helping narrow health inequality gaps.

Why This Inspires

After decades of watching COPD patients manage with only incremental improvements in care, healthcare teams finally have a genuinely new tool. Respiratory pharmacist Darush Attar-Zadeh emphasized that the real work starts now: training professionals and ensuring eligible patients can actually access the treatment quickly and fairly across the country.

The path from lab to living room took persistence. Regulators approved the drug back in 2023, but securing NHS funding required proving both effectiveness and value. Sanofi's Ahmed Moussa acknowledged that approval is just step one, with implementation being the next crucial phase.

For the estimated 9,000 to 12,000 English patients with both uncontrolled COPD and elevated eosinophils, this represents more than just another prescription option. It's a chance at fewer emergency room visits, less time gasping for breath, and more days feeling like themselves again.

The science behind dupilumab reveals why it works for this specific group: between 30 and 40 percent of COPD patients show signs of type 2 inflammation, marked by those raised eosinophil levels. Finally targeting that biological pathway opens doors that traditional bronchodilators and steroids couldn't unlock.

Healthcare systems now face the challenge of identifying eligible patients and getting this innovation into their hands without delay.